Ballentine Partners’s BeOne Medicines ONC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$542K Buy
1,481
+493
+50% +$169K 0.01% 559
2026
Q2
$282K Buy
988
+82
+9% +$24.2K ﹤0.01% 825
2026
Q1
$269K Buy
906
+28
+3% +$9.06K ﹤0.01% 795
2025
Q4
$267K Buy
878
+126
+17% +$41.2K ﹤0.01% 769
2025
Q3
$256K Buy
+752
New +$228K ﹤0.01% 801

Other funds holding ONC

Ballentine Partners's ONC Position: Q3 2026 in Review

Ballentine Partners increased its BeOne Medicines (ONC) stake by 50% in Q3 2026, buying an estimated $169K and bringing the position to 1,481 shares worth $542K. The position accounts for 0.01% of the portfolio, ranked #559.

Ballentine Partners first reported a position in ONC in Q3 2025 and has held it in 5 quarters since. 325 funds tracked by Wall St. Rank hold ONC as of Q3 2026.

  • Ballentine Partners held 1,481 shares of BeOne Medicines worth $542K as of Q3 2026.
  • Ballentine Partners bought 493 BeOne Medicines shares in Q3 2026, an estimated $169K.
  • BeOne Medicines made up 0.01% of Ballentine Partners's portfolio in Q3 2026, its #559 holding.
  • Ballentine Partners first reported a position in BeOne Medicines in Q3 2025 and has held it in 5 quarters since.
  • 325 funds tracked by Wall St. Rank held BeOne Medicines as of Q3 2026.

Based on Ballentine Partners's 13F filing for Q3 2026, filed 13 Nov 2026.